Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study

T. A. Ashfield\(^1\), H. E. Syddall\(^2\), H. J. Martin\(^2\), E. M. Dennison\(^2\), C. Cooper\(^2\), A. Aihie Sayer\(^{1,2}\)

\(^1\)Academic Geriatric Medicine
\(^2\)MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK

Address correspondence to: A. A. Sayer, MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK. Tel: (+44) 23 8077 7624; Fax: (+44) 23 8070 4021. Email: aas@mrc.soton.ac.uk

Abstract

Background: reduced grip strength is associated with adverse health consequences, and there is interest in identifying modifiable influences. Cardiovascular drugs are commonly used by older people, but their effect on muscle strength is unclear.

Methods: we investigated associations between cardiovascular drug use and grip strength among 1,572 men and 1,415 women, aged 59–73, who participated in the Hertfordshire Cohort Study.

Results: forty-five percent of participants were taking a cardiovascular drug. Furosemide was associated with average decreases in grip strength of 3.15 kg (95% confidence interval [CI] 0.90, 5.39, \(P<0.01\)) among men and 2.35 kg (95% CI 0.93, 3.77, \(P<0.01\)) among women after adjustment for age and height. Corresponding differences for nitrates were 1.84 kg (95% CI 0.29, 3.39, \(P=0.02\)) among men and 3.66 kg (95% CI 1.99, 5.33, \(P<0.01\)) among women. Calcium channel blockers and fibrates were associated with reduced grip among women. Statins were not associated with grip. The associations between grip strength and nitrate use in men and nitrate and fibrate use in women were robust to additional adjustment for comorbidity.

Conclusions: use of some cardiovascular drugs is associated with reduced grip strength in older people. These findings have potential implications for the functional ability of older people treated with these drugs.

Keywords: grip strength, sarcopenia, cardiovascular drugs, ageing, elderly

Introduction

Grip strength is a useful marker of muscle function and sarcopenia (the age-related decline in skeletal muscle mass, strength and quality) \([1]\). There is growing evidence that reduced grip strength in older people is associated with adverse outcomes including morbidity \([2]\), disability \([3]\), falls \([3]\), higher fracture rates \([4]\), increased length of hospital stay \([5]\) and mortality \([3]\). There is therefore considerable interest in identification of modifiable life course influences on muscle strength.

Ageing is associated with an accumulation of prescribed medication, and the prevalence of polypharmacy (use of more than five medications) has increased \([6]\). Chronic disease is just one cause; new drugs, new indications, lower thresholds for treatment and inappropriate prescribing also contribute \([7, 8]\). Even with appropriate prescribing, the risk of adverse drug reactions, of which older people are at increased risk \([9]\), rises with the use of more medications \([10]\). The National Service Framework for Older People identifies that use of four or more medications is a risk factor for falling and recommends discontinuation of excessive medication \([11]\).

Cardiovascular drugs are the most commonly prescribed drugs by therapeutic group in the UK \([12]\). Some of these drugs are associated with known adverse effects on skeletal muscle and physical function; for example, diuretics are associated with falls through a number of mechanisms including postural hypotension \([13]\), and statins are associated with myopathy \([14]\) and possibly impaired muscle function \([15]\). However, there is also some evidence for beneficial effects of cardiovascular drugs on muscle, physical performance and frailty. For example, a study of 641 older women with hypertension but no heart failure participating in the longitudinal Women’s Aging and Health Study found that angiotensin converting enzyme (ACE) inhibitor treat-
ment appeared to halt or slow decline in muscle strength [16]. The proposed mechanism is a direct beneficial effect on body composition through the actions of ACE inhibitors on inflammation and metabolic pathways rather than on lowering blood pressure [17].

Few studies have described the associations between the use of a range of commonly prescribed cardiovascular drugs and muscle strength in one group of older people. We therefore investigated the relationship between grip strength and use of cardiovascular drugs using data from the community-dwelling older men and women who participated in the Hertfordshire Cohort Study (HCS).

Methods
Study participants comprised 1,572 men and 1,415 women aged 59–73 years who participated in home interviews and clinic visits for the HCS between 1998 and 2004 [18]. Details of all currently used over the counter or prescription medications were coded to the British National Formulary. Grip strength was measured three times on each side using a Jamar handgrip dynamometer, and the best of the six measurements was used to characterise maximum muscle strength. Please see Appendix 1 on the journal website (http://www.ageing.oxfordjournals.org/) for a full description of the study population and methodology.

Statistical methods
Multiple linear regression was used to analyse the association between maximum grip strength and total number of medications used, with and without adjustment for age and height. Subsequently, multiple linear regression was used to analyse differences in maximum grip strength between users versus non-users of each individual cardiovascular medication in turn. Analyses were conducted: without adjustment for potential confounders; with adjustment for age and height; with adjustment for age, height and also co-morbidity (ischaemic heart disease [IHD], hypertension, diabetes mellitus and history of stroke/transient ischaemic attack [TIA]) and walking speed as a marker of physical activity.

Multiple linear regression was also used to analyse the unadjusted, and age and height adjusted, associations between maximum grip strength and each co-morbidity and walking speed in turn. Data were analysed for men and women separately throughout using Stata release 10.

Results
Summary characteristics
The average age of HCS participants was 66.1 years (standard deviation [SD] 2.9). Average height was 174.2 cm for men and 160.8 cm for women. Average grip strength was higher among men (44.0 kg [SD 7.5]) than women (26.5 [SD 5.8]). Men used a median of one medication (inter-quartile range [IQR] 0, 3) and women a median of two (IQR 1, 4). The prevalences of IHD, stroke/TIA, diabetes, hypertension and slower than normal walking speed were 14.5, 5.0, 14.8, 39.9 and 28.6%, respectively, among men, and 9.1, 2.8, 14.3, 40.7 and 26.9%, respectively, among women. Grip strength was positively related to height (men $r=0.29$, $P<0.01$; women $r=0.19$, $P<0.01$) and inversely related to age (men $r=-0.18$, $P<0.01$; women $r=-0.18$, $P<0.01$).

The percentage of men and women who used at least one cardiovascular medication were 44.9 and 44.1%, respectively. The proportions of men using thiazide diuretics, loop diuretics, β-blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers (CCBs), nitrates, α-blockers, aspirin, statins and fibrates were 10.2, 2.3, 12.9, 12.0, 2.9, 9.8, 5.0, 6.3, 21.2, 13.0 and 0.9%, re-
Grip strength in relation to total number of medications taken

Grip strength decreased progressively with increasing numbers of medications used (Figure 1). After adjustment for age and height, each additional medication used was associated with an average reduction in grip strength of 0.36 kg (95% confidence interval [CI] 0.21, 0.52, \( P < 0.01 \)) among men and 0.42 kg (95% CI 0.31, 0.53, \( P < 0.01 \)) among women.

Grip strength in relation to use of individual cardiovascular drugs

The associations between grip strength and furosemide, nitrate, statin, CCB and fibrate use, co-morbidity and physical activity are presented in Figures 2 (for men) and 3 (for women). There were no significant associations (\( P < 0.05 \)) between grip strength and thiazide diuretic, \( \beta \)-blocker, ACE inhibitor, angiotensin II antagonist, \( \alpha \)-blocker or aspirin use in unadjusted or adjusted analyses, and these results have not been included in the figures.

Furosemide

Furosemide use was associated with a reduction in grip strength in men and women in unadjusted analyses (average reductions in grip strength [95% CI]: men 4.17 kg [1.69, 6.65], \( P < 0.01 \); women 2.79 kg [1.31, 4.28], \( P < 0.01 \)). These associations were robust to adjustment for age and height (average age and height adjusted reductions in grip strength: men 3.15 kg [0.90, 5.39], \( P = 0.04 \); women 2.35 kg [0.93, 3.77], \( P < 0.01 \)) but became non-significant after additional adjustment for co-morbidity and physical activity (average age, height, co-morbidity and physical activity adjusted reductions in grip strength: men 1.89 kg [−0.41, 4.19], \( P = 0.11 \); women 1.09 kg [−0.34, 2.52], \( P = 0.14 \)).

Nitrates

Nitrate use was associated with a significant reduction in grip strength in men and women in unadjusted analyses (average reductions in grip strength [95% CI]: men 2.65 kg [0.94, 4.36], \( P < 0.01 \); women 4.21 kg [2.45, 5.96], \( P < 0.01 \)). These associations remained after full adjustment for co-morbidity and physical activity (average age, height, co-morbidity and physical activity adjusted reductions in grip strength: men 1.72 kg [0.05, 3.41], \( P = 0.04 \); women 2.46 kg

---

Figure 2. Association between grip strength, cardiovascular drug use, co-morbidity and physical activity among men. The figure shows the average reduction in grip strength in relation to medication use, co-morbidity and walking speed. Average reductions in grip strength were derived from linear regression models which were firstly unadjusted, then adjusted for age and height and then (for medication use analyses only) adjusted for age, height, co-morbidity and walking speed as a marker of physical activity. Error lines represent 95% confidence intervals. \( * P < 0.05 \). CCBs, calcium channel blockers; IHD, ischaemic heart disease; BP, hypertension; <Normal speed, slower than normal walking speed.
Figures 2 and 3 show that the reductions in grip strength associated with nitrate use were of a similar, or greater, magnitude than the reductions in grip strength associated with diabetes (average age and height adjusted reductions in grip strength for diabetics compared with non-diabetics: men 1.75 kg \([-0.80, 2.70]\), \(P<0.01\); women 0.89 kg \([-0.07, 1.71]\), \(P=0.03\)).

**Statins**

Grip strength was not associated with statin use in men or women, in unadjusted (average unadjusted reductions in grip strength [95% CI]: men 0.24 kg \([-0.86, 1.34]\), \(P=0.67\); women 0.52 kg \([-0.48, 1.53]\), \(P=0.31\)) or adjusted analyses.

**CCBs**

Use of CCBs was associated with a significant reduction in grip strength in men and women in unadjusted analyses (average reductions in grip strength [95% CI]: men 1.71 kg \([0.46, 2.95]\), \(P<0.01\); women 1.59 kg \([0.54, 2.65]\), \(P<0.01\)) but age and height adjustment attenuated this association in men (average age and height adjusted reductions in grip strength: men 0.90 kg \([-0.24, 2.03]\), \(P=0.12\); women 1.45 kg \([0.45, 2.45]\), \(P<0.01\)) and full adjustment attenuated the association in women (average age, height, co-morbidity and physical activity adjusted reductions in grip strength: men 0.14 kg \([-1.02, 1.31]\), \(P=0.81\); women 0.80 kg \([-0.20, 1.80]\), \(P=0.12\)).

**Fibrates**

Fibrates were only taken by 0.9% men, and their use was not associated with grip strength (\(P=0.96\) unadjusted; \(P=0.74\) fully adjusted). However, the 1.1% of women who used fibrates had significantly lower grip strength than non-users (average unadjusted reductions in grip strength [95% CI]: 3.75 kg \([0.82, 6.08]\), \(P=0.02\); average fully adjusted reductions in grip strength [95% CI]: 3.31 kg \([0.50, 6.11]\), \(P=0.02\)). The magnitude of this difference was of similar or greater magnitude than the differences in grip strength associated with co-morbidity or physical activity among women (Figure 3).

**Discussion**

This study has demonstrated that the use of some cardiovascular drugs is associated with reduced grip strength in older people. Among community-dwelling older men and women...
Grip strength and cardiovascular drug use in older people

who participated in the HCS, use of furosemide, nitrates and CCBs among men and women and fibrates among women was associated with reduced grip strength. Nitrate use in men and nitrate and fibrate use in women was associated with reduced grip strength, independent of age, height and co-morbidity. These findings may reflect a direct adverse effect of specific drugs or the underlying process of cardiovascular disease on muscle function in older people. These novel findings have potential implications for the functional ability of older people treated with cardiovascular drugs, particularly people who are functionally impaired or frail.

The average reductions in grip strength associated with cardiovascular drug use in this study were sizeable and clinically relevant. For example, Ensrud et al. [19] have shown that a 5 kg reduction in grip strength is associated with an odds ratio of 1.5 for difficulty in performing three or more activities of daily living, and analysis of HCS data suggests that a 2 kg reduction in grip strength is equivalent to approximately 5 years of chronological ageing (data not shown). Other functional limitations associated with reduced grip strength include walking impairment, lower self-reported physical function and increased morbidity such as impaired metabolic function [20] and reduced quality of life [21].

Animal studies have indicated that furosemide can affect the membrane potential of skeletal muscle [22], but the only documented cases of furosemide-associated muscle weakness in humans have involved metabolic disturbances of magnesium [23] or potassium [24]. In this study, furosemide was associated with reduced grip strength in men and women after adjustment for age and height but not after additional adjustment for co-morbidity and physical activity. The possible additional confounding effect of heart failure could not be accounted for because an appropriate marker (e.g. systolic ejection fraction) was not available in the HCS study.

Nitrate use was robustly associated with reduced grip strength among men and women in this study. Nitrates exert their therapeutic effect through nitric oxide donation. They are generally regarded as selective to smooth muscle, and myopathy is not a recognised side effect [25]. However, nitric oxide synthase is present in skeletal muscle of all mammals, and experimental animal evidence suggests that exogenous nitrates can attenuate force production of limb muscles in situ [26].

The exact type of CCB used was not specified in the HCS data, but it is likely that most people were taking dihydropyridine types (e.g. amlodipine). The findings in this study are consistent with a previous longitudinal study in which CCBs were found to be a risk factor for loss of muscle strength [27]. In a case-control study, amlodipine and verapamil were associated with altered neuromuscular transmission as indicated by Electromyography (EMG) [28].

Fibrates were associated with reduced grip strength in HCS women. This could be a true direct effect because fibrates have known myopathic potential which may be caused by calcium-mediated apoptosis of myocytes [29]. The gender difference in this association could arise from gender specific differences in drug handling or effects on skeletal muscle. Alternatively, these medications may only have an appreciable effect on muscle of lower strength.

Statin use was prevalent (13.0% men, 9.8% women) but was not associated with impaired grip strength in men or women. Findings from other observational studies have been conflicting. For example, a longitudinal study of community-dwelling older men and women in Australia found that statin use was associated with lower leg strength [15]. However, a study of older people from the United States demonstrated no difference between statin users and non-users with regard to muscle strength [30]. A recent small randomised controlled trial of a high dose statin in 10 men and women aged 55–76 years found that 12 week treatment was associated with a decrease in Low Density Lipoprotein (LDL) and total cholesterol levels but no myalgic or myopathic symptoms and no significant change in maximal muscle strength, power or endurance [31]. The link however between statin use, myopathy and muscle strength remains to be fully explored [32].

ACE inhibitor use was also prevalent in this study (men 12.0%, women 10.3%) but we were unable to demonstrate any beneficial effect on muscle strength in either gender. This contrasts with findings from the Women's Aging and Health Study where longitudinal data were available [16]. There is also evidence from a randomised controlled trial of 120 functionally impaired older people with no heart failure that ACE inhibitor treatment is associated with improved 6 minute walking distance. However, there was no associated change in chair rises used as a marker of lower leg strength and the trial did not include any direct measures of muscle strength [33].

Our study had several limitations. Firstly, the data were cross-sectional and causality cannot be implied. However, the average reductions in grip strength were sizeable and of similar or greater magnitude than differences in grip strength according to co-morbidity, suggesting that the drugs may have a direct effect on muscle. Secondly, many statistical tests were conducted which raises the possibility of false positive results. We have addressed this by replicating the findings for nitrates and furosemide in the smaller Hertfordshire Ageing Study (data not shown) [34]. Thirdly, although we have adjusted for potentially important co-morbidities, we were not able to allow for disease severity or duration, and residual confounding by other chronic diseases is a possibility. However, the non-significant association between grip strength and use of statins argues against the possibility that our results were simply due to residual confounding by co-morbidity because users of statins will have a similar co-morbidity profile as users of the other cardiovascular drugs (e.g. furosemide and fibrates) that were associated with grip strength.

Our study also had many strengths. Firstly, we analysed a large dataset of community-dwelling older men and women whose cardiovascular drug use was ascertained by a trained research nurse at a face-to-face home interview. Secondly, grip strength was directly measured at clinic as a marker of sarcopenia. Thirdly, the data were rigorously collected according to strict protocols by trained research nurses and
Reduced grip strength is associated with adverse health consequences, and there is interest in identifying modifiable influences. Cardiovascular drugs are commonly used by older people, but their effect on muscle strength is unclear.

- Among HCS participants, use of furosemide, nitrates and CCBs among men and women and fibrates among women was associated with reduced grip strength. Nitrate use in men and nitrate and fibrate use in women was associated with lower grip strength, independent of age, height and co-morbidity.
- Use of some cardiovascular drugs is associated with reduced grip strength in older people. These findings have potential implications for the functional ability of older people treated with these drugs.

Acknowledgements

We thank the men and women who participated in the Hertfordshire Cohort Study, the Hertfordshire General Practitioners and the nurses and doctors who conducted the fieldwork.

Conflicts of interest

There is no conflict of interest to declare.

Supplementary data

Supplementary data mentioned in the text is available to subscribers at the journal website http://ageing.oxfordjournals.org

Funding

This work was supported by the Medical Research Council and University of Southampton, UK.

References

7. Gorard DA. Escalating polypharmacy; QJM 2006; 99: 797–800.
Ageing and gait variability—a population-based study of older people

Michele L. Callisaya1, Leigh Blizzard1, Michael D. Schmidt2, Jennifer L. McGinley3, Velandai K. Srikanth1,4

1Menzies Research Institute, University of Tasmania, Private Bag 23, Hobart, Tasmania 7001, Australia
2Department of Kinesiology, University of Georgia, 101 Ramsey Center, 330 River Road, Athens, GA 30602, USA
3Gait CCRE, Hugh Williamson Gait Analysis Service, Murdoch Childrens Research Institute, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia
4Department of Medicine, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia

Address correspondence to: M. L. Callisaya. Tel: (+61) 3 6226 7700; Fax (+61) 3 6226 7704. Email: michele@utas.edu.au

Abstract

Background: gait variability may be an important predictor of falls risk, but its characteristics are poorly understood.

Objective: to examine the relationship between age and gait variability in a population-based sample of older people.

Design: cross-sectional study.

Methods: in people aged 60–86 years (n=412), temporal and spatial gait variability measures were recorded with a GAITRite walkway. Regression analysis was used to model the relationship between age and gait variability adjusting for height, weight and self-reported chronic disease. Further adjustment was made for gait speed to examine its influence on the associations.

Results: older age was associated with greater variability (P<0.05) in all gait measures. All relationships were linear, except that between age and step time variability, which was curvilinear in women. Adjusting for gait speed changed the magnitude of the age coefficient by 62–86% for temporal variability measures, 25% for step length variability and 5–12% for step width variability.

Age and Ageing 2010; 39: 191–197

Published electronically 18 January 2010

© The Author 2010. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org